Related Experiment Video
Updated: Apr 26, 2026

Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain
Published on: August 28, 2012
ATBF1 is a novel amyloid-β protein precursor (AβPP) binding protein that affects AβPP expression
Kyung-Ok Uhm1, Mi-Jeong Kim1, Makoto Kawaguchi2
1Department of Alzheimer's Disease Research, Research Institute, National Center for Geriatrics and Gerontology (NCGG), Morioka, Obu, Aichi, Japan.
AT-motif binding factor 1 (ATBF1) is elevated in Alzheimer's disease (AD) brains and increases amyloid-β precursor protein (AβPP) levels, leading to higher amyloid-β (Aβ) production. Reducing ATBF1 lowers AβPP and Aβ, suggesting ATBF1 as a therapeutic target for AD.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Amyloid-β protein precursor (AβPP) processing and amyloid-β (Aβ) production are central to Alzheimer's disease (AD) pathogenesis.
- The cytoplasmic C-terminal domain of AβPP interacts with regulatory proteins, influencing Aβ production.
- Previous studies indicated elevated AT-motif binding factor 1 (ATBF1) in aged mouse brains and its role in neuronal death.
Purpose of the Study:
- To investigate the role of ATBF1 in Alzheimer's disease (AD) brain pathology.
- To determine if ATBF1 directly interacts with AβPP and affects Aβ production.
- To explore ATBF1 as a potential therapeutic target for AD.
Main Methods:
- Immunohistochemistry on human brain samples to assess ATBF1 levels in AD patients.
- Cell-based assays (HEK293T, SH-SY5Y) involving co-transfection with ATBF1 and AβPP695.
- Western blotting to quantify AβPP, soluble AβPP (sAβPP), and Aβ levels.
- ATBF1 knockdown experiments using siRNA in AβPP-overexpressing cells.
Main Results:
- ATBF1 levels were significantly increased in the cytoplasm of hippocampal neurons in Alzheimer's disease (AD) brains compared to non-AD controls.
- Overexpression of ATBF1 with AβPP695 in HEK293T and SH-SY5Y cells increased steady-state AβPP levels by direct binding to the AβPP cytoplasmic domain (amino acids 666-690).
- This interaction led to elevated Aβ production and increased cellular and soluble AβPP (sAβPP) levels, without altering secretase activity.
- Knockdown of endogenous ATBF1 in AβPP-overexpressing HEK293 cells reduced cellular AβPP, sAβPP, and Aβ levels.
Conclusions:
- ATBF1 is upregulated in the cytoplasm of neurons in Alzheimer's disease (AD) brains.
- ATBF1 directly binds to the cytoplasmic C-terminal domain of AβPP, enhancing AβPP levels and subsequently increasing Aβ production.
- ATBF1 represents a novel AβPP binding protein and a potential therapeutic target for Alzheimer's disease (AD).
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Mitochondrial Precursor Proteins
Most of the mitochondrial...

